These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 23714252)
1. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern. Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252 [TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of 103 ovarian serous and mucinous tumors. Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228 [TBL] [Abstract][Full Text] [Related]
6. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101 [TBL] [Abstract][Full Text] [Related]
7. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645 [TBL] [Abstract][Full Text] [Related]
8. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
9. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
10. Na K; Sung JY; Kim HS Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585 [TBL] [Abstract][Full Text] [Related]
12. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
13. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
14. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864 [TBL] [Abstract][Full Text] [Related]
15. Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics. Vergara D; Tinelli A; Martignago R; Malvasi A; Chiuri VE; Leo G Curr Cancer Drug Targets; 2010 Feb; 10(1):107-16. PubMed ID: 20088785 [TBL] [Abstract][Full Text] [Related]
16. [Updates on histologic grading and pathogenesis of ovarian serous carcinomas]. Shen Y; Yang F; Liu JS Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):507-10. PubMed ID: 22169636 [No Abstract] [Full Text] [Related]
17. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420 [TBL] [Abstract][Full Text] [Related]
18. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
19. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma? Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]